Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Research-driven pharmaceutical company focused on oncology, metabolism, immunology, central nervous system and anti-infectives. It markets seven innovative drugs of its own, among them aumolertinib for lung cancer, flumatinib for chronic myeloid leukaemia, tenofovir amibufenamide for hepatitis B and PEGylated loxenatide. It reports plants certified by the FDA, EMA and the Japanese agency. Founded in 1995 in Lianyungang.